MCID: CRB088
MIFTS: 39

Cerebral Atrophy

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Cerebral Atrophy

MalaCards integrated aliases for Cerebral Atrophy:

Name: Cerebral Atrophy 51 29 69

Classifications:



Summaries for Cerebral Atrophy

NINDS : 51 Cerebral atrophy is a common feature of many of the diseases that affect the brain. Atrophy of any tissue means loss of cells. In brain tissue, atrophy describes a loss of neurons and the connections between them. Atrophy can be generalized, which means that all of the brain has shrunk; or it can be focal, affecting only a limited area of the brain and resulting in a decrease of the functions that area of the brain controls. If the cerebral hemispheres (the two lobes of the brain that form the cerebrum) are affected, conscious thought and voluntary processes may be impaired. Associated Diseases/Disorders: The pattern and rate of progression of cerebral atrophy depends on the disease involved. Diseases that cause cerebral atrophy include: stroke and traumatic brain injury Alzheimer’s disease, Pick’s disease, and fronto-temporal dementia cerebral palsy, in which lesions (damaged areas) may impair motor coordination Huntington’s disease, and other hereditary diseases that are associated with genetic mutations leukodystrophies, such as Krabbe disease, which destroy the myelin sheath that protects axons mitochondrial encephalomyopathies, such as Kearns-Sayre syndrome, which interfere with the basic functions of neurons multiple sclerosis, which causes inflammation, myelin damage, and lesions in cerebral tissue infectious diseases, such as encephalitis, neurosyphilis, and AIDS, in which an infectious agent or the inflammatory reaction to it destroys neurons and their axons Symptoms of cerebral atrophy: Many diseases that cause cerebral atrophy are associated with dementia, seizures, and a group of language disorders called the aphasias.  Dementia is characterized by a progressive impairment of memory and intellectual function that is severe enough to interfere with social and work skills. Memory, orientation, abstraction, ability to learn, visual-spatial perception, and higher executive functions such as planning, organizing, and sequencing may also be impaired. Seizures can take different forms, appearing as disorientation, repetitive movements, loss of consciousness, or convulsions. Aphasias are a group of disorders characterized by disturbances in speaking and understanding language. Receptive aphasia causes impaired comprehension. Expressive aphasia is reflected in odd choices of words, the use of partial phrases, disjointed clauses, and incomplete sentences.

MalaCards based summary : Cerebral Atrophy is related to ceroid lipofuscinosis, neuronal, 1 and keratosis follicularis, dwarfism, and cerebral atrophy, and has symptoms including headache An important gene associated with Cerebral Atrophy is VPS53 (VPS53, GARP Complex Subunit). The drugs Interferon beta-1a and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and pineal, and related phenotypes are mortality/aging and skeleton

Wikipedia : 72 Cerebral atrophy is a common feature of many of the diseases that affect the brain.Atrophy of any tissue... more...

Related Diseases for Cerebral Atrophy

Diseases in the Cerebral Atrophy family:

Autosomal Recessive Cerebral Atrophy

Diseases related to Cerebral Atrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 142)
id Related Disease Score Top Affiliating Genes
1 ceroid lipofuscinosis, neuronal, 1 30.9 CLN6 DNAJC5
2 keratosis follicularis, dwarfism, and cerebral atrophy 12.1
3 autosomal recessive cerebral atrophy 11.8
4 pontocerebellar hypoplasia, type 2e 11.5
5 prieto syndrome 11.4
6 incontinentia pigmenti 11.0
7 aicardi-goutieres syndrome 7 10.8
8 aicardi-goutieres syndrome 1, dominant and recessive 10.8
9 aicardi-goutieres syndrome 3 10.8
10 epileptic encephalopathy, early infantile, 17 10.8
11 neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination 10.8
12 pontocerebellar hypoplasia type 2d 10.8
13 asparagine synthetase deficiency 10.8
14 pontocerebellar hypoplasia type 2a 10.8
15 prieto x-linked mental retardation syndrome 10.8
16 cerebritis 10.8
17 aicardi-goutieres syndrome 6 10.6
18 3-methylglutaconic aciduria, type viii 10.6
19 neurodevelopmental disorder with hypotonia, seizures, and absent language 10.6
20 encephalopathy, familial, with neuroserpin inclusion bodies 10.6
21 ceroid lipofuscinosis, neuronal, 7 10.6
22 epileptic encephalopathy, early infantile, 51 10.6
23 ceroid lipofuscinosis, neuronal, 8 10.6
24 ceroid lipofuscinosis, neuronal, 10 10.6
25 ceroid lipofuscinosis, neuronal, 2 10.6
26 encephalopathy, neonatal severe, with lactic acidosis and brain abnormalities 10.6
27 aicardi-goutieres syndrome 2 10.6
28 ceroid lipofuscinosis, neuronal, 5 10.6
29 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.6
30 ceroid lipofuscinosis, neuronal, 6 10.6
31 ceroid lipofuscinosis, neuronal, kufs type, adult onset 10.6
32 galloway-mowat syndrome 10.6
33 ceroid lipofuscinosis, neuronal, 3 10.6
34 neurodevelopmental disorder with involuntary movements 10.6
35 peho syndrome 10.6
36 aicardi-goutieres syndrome 4 10.6
37 aicardi-goutieres syndrome 5 10.6
38 ceroid lipofuscinosis, neuronal, 4, parry type 10.6
39 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.6
40 mohr-tranebjaerg syndrome 10.6
41 oculopalatocerebral syndrome 10.6
42 aicardi-goutieres syndrome 10.6
43 cerebellum agenesis hydrocephaly 10.6
44 dementia 10.2
45 cngb3-related stargardt disease 1 10.1 CLN6 DNAJC5
46 diarrhea, chronic, with villous atrophy 10.1 CLN6 DNAJC5
47 hydrocephalus 10.1
48 adult-onset nemaline myopathy 10.1 CLN6 DNAJC5
49 retinal degeneration, late-onset, autosomal dominant 10.0 CLN6 DNAJC5
50 macular dystrophy with central cone involvement 10.0 CLN6 DNAJC5

Graphical network of the top 20 diseases related to Cerebral Atrophy:



Diseases related to Cerebral Atrophy

Symptoms & Phenotypes for Cerebral Atrophy

UMLS symptoms related to Cerebral Atrophy:


headache

MGI Mouse Phenotypes related to Cerebral Atrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 9.43 ADAR CLN6 DNAJC5 NACC1 RNASEH2B VPS53
2 skeleton MP:0005390 8.92 ADAR CLN6 NACC1 VPS53

Drugs & Therapeutics for Cerebral Atrophy

Drugs for Cerebral Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Interferon beta-1a Approved, Investigational Phase 4,Phase 3,Phase 2 145258-61-3 6438354
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Memantine Approved, Investigational Phase 4 19982-08-2 4054
4
Interferon beta-1b Approved Phase 4,Phase 2 145155-23-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
6
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
10
Cysteamine Approved, Investigational Phase 4 60-23-1 6058
11
Galantamine Approved Phase 4,Phase 3 357-70-0 9651
12
Acetylcholine Approved Phase 4 51-84-3 187
13
Glatiramer Acetate Approved, Investigational Phase 4,Phase 1,Phase 2 147245-92-9 3081884
14
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
17 Excitatory Amino Acid Antagonists Phase 4,Phase 2
18 Excitatory Amino Acids Phase 4,Phase 2
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
20 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
21 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
22 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
23 Interferon-beta Phase 4,Phase 3,Phase 2
24 interferons Phase 4,Phase 3,Phase 2
25 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
27 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Phase 1
28 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
29 Antirheumatic Agents Phase 4,Phase 1,Phase 2
30 Antiparkinson Agents Phase 4,Phase 3
31 Dopamine Agents Phase 4
32 Fingolimod Hydrochloride Phase 4,Phase 1,Phase 2
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Antiemetics Phase 4
35 Antineoplastic Agents, Hormonal Phase 4,Phase 2
36 Autonomic Agents Phase 4,Phase 3,Phase 2
37 BB 1101 Phase 4
38 Dexamethasone acetate Phase 4 1177-87-3
39 Gastrointestinal Agents Phase 4
40 glucocorticoids Phase 4
41 Hormone Antagonists Phase 4,Phase 2
42 Hormones Phase 4,Phase 2
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
44 Methylprednisolone acetate Phase 4
45 Methylprednisolone Hemisuccinate Phase 4
46 Prednisolone acetate Phase 4
47 Prednisolone hemisuccinate Phase 4
48 Prednisolone phosphate Phase 4
49 Antimetabolites Phase 4,Phase 2
50 Antimetabolites, Antineoplastic Phase 4

Interventional clinical trials:

(show top 50) (show all 147)

id Name Status NCT ID Phase Drugs
1 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
2 Validation of DaTscan for Detection of Parkinson Disease Related Disorders Unknown status NCT02138682 Phase 4 l-123 Ioflupane
3 A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease Completed NCT00862940 Phase 4 Memantine;Placebo
4 Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease) Completed NCT00334906 Phase 4 memantine HCl
5 Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms Completed NCT01333501 Phase 4 Fingolimod;Interferon beta 1b
6 Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS Completed NCT00232193 Phase 4
7 Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS Completed NCT00168766 Phase 4 Interferon-beta-1a (Avonex) plus methylprednisolone
8 AVONEX® Combination Trial - "ACT" Completed NCT00112034 Phase 4 Methotrexate;IV methylprednisolone
9 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis Completed NCT00028262 Phase 4 Cystagon
10 Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Completed NCT00493116 Phase 4 Interferon-beta-1a;methylprednisolone
11 The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease Completed NCT01921972 Phase 4 Galantamine CR;Memantine;Placebo
12 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
13 Effect of Fingolimod on Neurodegeneration Terminated NCT02575365 Phase 4 0,5 mg Fingolimod
14 Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate Terminated NCT00203047 Phase 4 Glatiramer Acetate;Placebo;Prednisone
15 Vagus Nerve Stimulation to Augment Recovery From Minimally Conscious or Persistently Vegetative States After Traumatic Brain Injury Unknown status NCT01260090 Phase 3
16 Sunphenon in Progressive Forms of Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3 Sunphenon EGCG;Placebo
17 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3 lipoic acid;Placebo
18 Magnetic Stimulation Therapy for Treating Vascular Depression Completed NCT00044798 Phase 3 Citalopram
19 A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment Completed NCT00236574 Phase 3 Galantamine hydrobromide
20 Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Completed NCT01110720 Phase 2, Phase 3 Davunetide;Placebo
21 Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline Completed NCT00878631 Phase 2, Phase 3 hypertonic saline mixed with dextran;Normal Saline
22 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed NCT02008721 Phase 3 EGCG as putative neuroprotective agent;Placebo
23 Oculomotor Testing in the Differential Diagnosis of Dementia Completed NCT01577394 Phase 3
24 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3 dirucotide;Placebo
25 Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease Completed NCT00951834 Phase 2, Phase 3 Epigallocatechin-Gallate;Placebo
26 Omega-3 Fatty Acid Treatment in Multiple Sclerosis Completed NCT00360906 Phase 2, Phase 3 Triomar™ (omega-3 fatty acids)
27 Study About Efficacy and Safety to Treat Multi-System-Atrophy Completed NCT00146809 Phase 3 Minocyline
28 Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Recruiting NCT02201108 Phase 3 Teriflunomide HMR1726;Placebo
29 Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Recruiting NCT01671384 Phase 3 Valproate, Levocarnitine;Placebo
30 National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Ph Active, not recruiting NCT02937285 Phase 3 Interferon beta 1a;Mitoxantrone
31 BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) Active, not recruiting NCT00835770 Phase 3 dimethyl fumarate;Placebo
32 Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome Not yet recruiting NCT03122652 Phase 3 Teriflunomide 14 MG Oral Tablet [Aubagio];Placebo Oral Tablet
33 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3 dimethyl fumarate
34 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3 dirucotide
35 Phase 3 IGIV, 10% in Alzheimer´s Disease Terminated NCT01524887 Phase 3
36 Study of Rifampicin in Multiple System Atrophy Terminated NCT01287221 Phase 3 Rifampicin;placebo
37 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2 Andrographolides;placebo
38 A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis Unknown status NCT00217295 Phase 2 Avonex and Topamax
39 The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis Unknown status NCT00917839 Phase 2 lamotrigine
40 Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination Unknown status NCT01627938 Phase 2 Dexrazoxane (DRZ) plus Mitoxantrone (MX);Placebo plus Mitoxantrone (MX)
41 Investigation of Simvastatin in Secondary Progressive Multiple Sclerosis Completed NCT00647348 Phase 2 Simvastatin;Placebo
42 Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis Completed NCT01684761 Phase 2
43 Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Completed NCT01982942 Phase 2 ibudilast;Placebo
44 Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) Completed NCT00525668 Phase 1, Phase 2 epigallocatechin-gallate (Sunphenon);placebo
45 Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation Completed NCT00342381 Phase 2 3,4-diaminopyridine;Placebo
46 Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b Completed NCT00942591 Phase 2 Interferon beta 1b;Atorvastatin
47 Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis Completed NCT01377870 Phase 1, Phase 2
48 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Completed NCT00257855 Phase 2 Lamotrigine
49 Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b Completed NCT01111656 Phase 2 Interferon beta-1b group;Interferon beta-1b/Atorvastatin group
50 Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study) Completed NCT01357681 Phase 2 (2)-epigallocatechin-3-gallate (EGCG);Placebo

Search NIH Clinical Center for Cerebral Atrophy

Genetic Tests for Cerebral Atrophy

Genetic tests related to Cerebral Atrophy:

id Genetic test Affiliating Genes
1 Cerebral Atrophy 29

Anatomical Context for Cerebral Atrophy

MalaCards organs/tissues related to Cerebral Atrophy:

39
Brain, Testes, Pineal, Kidney, Retina, Spinal Cord, Temporal Lobe

Publications for Cerebral Atrophy

Articles related to Cerebral Atrophy:

(show top 50) (show all 405)
id Title Authors Year
1
Cockayne syndrome with intracranial calcification, hypomyelination, and cerebral atrophy. ( 28149095 )
2017
2
A novel TRAPPC11 mutation in two Turkish families associated with cerebral atrophy, global retardation, scoliosis, achalasia and alacrima. ( 27707803 )
2017
3
White matter lesions characterise brain involvement in moderate to severe chronic obstructive pulmonary disease, but cerebral atrophy does not. ( 28629404 )
2017
4
Blood Pressure Control in Aging Predicts Cerebral Atrophy Related to Small-Vessel White Matter Lesions. ( 28555103 )
2017
5
Evolution of Cerebral Atrophy in a Patient with Super Refractory Status Epilepticus Treated with Barbiturate Coma. ( 28182114 )
2017
6
Association of White Matter Lesions, Cerebral Atrophy, Intracranial Extravascular Calcifications, and Ventricular-Communicating Hydrocephalus with Delirium Among Veterans. ( 28575905 )
2017
7
Interferon-I^ Is Associated with Cerebral Atrophy in Systemic Lupus Erythematosus. ( 28848179 )
2017
8
On aA remarkable syndrome of cerebral atrophy associated with hyperammonaemia in childhood. ( 27577062 )
2016
9
Reversible Cerebral Atrophy in Infantile Tremor Syndrome. ( 27395831 )
2016
10
Pontine and cerebral atrophy in Lennox-Gastaut syndrome. ( 26808205 )
2016
11
Impaired fasting blood glucose is associated to cognitive impairment and cerebral atrophy in middle-aged non-human primates. ( 28039490 )
2016
12
Does Side of Onset Influence the Pattern of Cerebral Atrophy in Parkinson's Disease? ( 27672378 )
2016
13
Long-Term Migration of a Deep Brain Stimulation (DBS) Lead in the Third Ventricle Caused by Cerebral Atrophy in a Patient with Anterior Thalamic Nucleus DBS. ( 26819942 )
2015
14
Cerebral atrophy in mild cognitive impairment: A systematic review with meta-analysis. ( 27239527 )
2015
15
Cerebral atrophy is linked to clinical severity and worsens with aging in patients with Pelizaeus-Merzbacher disease and Spastic Paraplegia type 2. ( 26531569 )
2015
16
Parry-Romberg syndrome associated with contralateral cerebral atrophy. ( 26771367 )
2015
17
Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. ( 25990306 )
2015
18
Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype. ( 26239178 )
2015
19
Retinal neurodegeneration on optical coherence tomography and cerebral atrophy. ( 25451722 )
2015
20
Quantification of Global Cerebral Atrophy in Multiple Sclerosis from 3T MRI Using SPM: The Role of Misclassification Errors. ( 25523616 )
2015
21
Progressive cerebral atrophy in neuromyelitis optica. ( 26359279 )
2015
22
VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2). ( 24577744 )
2014
23
Successful treatment of catatonia in a young man with schizophrenia and progressive diffuse cerebral atrophy. ( 24515696 )
2014
24
Subdural hemorrhages associated with antithrombotic therapy in infants with cerebral atrophy. ( 25113301 )
2014
25
Cerebral atrophy in a vitamin B12-deficient infant of a vegetarian mother. ( 25076673 )
2014
26
Association of SORL1 gene variants with hippocampal and cerebral atrophy and Alzheimer's disease. ( 24938503 )
2014
27
Cerebral atrophy and subdural haemorrhage after cerebellar and cerebral infarcts in an 8-month-old child after having been stung by a scorpion. ( 24962491 )
2014
28
Evolution of a symptomatic diffuse developmental venous anomaly with progressive cerebral atrophy in an atypical case of Sturge-Weber syndrome. ( 25547041 )
2014
29
Retraction. Francis GJ, Martinez JA, Liu WQ, Xu K, Ayer A, Fine J, Tuor UI, Glazner G, Hanson LR, Frey WH 2nd, Toth C. Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008 Dec;131(Pt 12):3311a8934. doi:10.1093/brain/awn288. ( 24860127 )
2014
30
Sturge-Weber syndrome with late onset hemiplegic migraine-like attacks and progressive unilateral cerebral atrophy. ( 24045571 )
2014
31
An autopsied case of corticobasal degeneration showing severe cerebral atrophy over a protracted disease course of 16 years. ( 25516199 )
2014
32
Cerebral atrophy and dementia in type 2 diabetes mellitus: report of two cases and review of literature. ( 24956625 )
2014
33
Global cerebral atrophy after subarachnoid hemorrhage: a possible marker of acute brain injury and assessment of its impact on outcome. ( 22890637 )
2013
34
Brain docosahexaenoic acid [DHA] incorporation and blood flow are increased in chronic alcoholics: a positron emission tomography study corrected for cerebral atrophy. ( 24098376 )
2013
35
Cerebral atrophy in elderly with subjective memory complaints. ( 23239111 )
2013
36
Cerebral atrophy is an independent risk factor for unfavorable outcome after spontaneous supratentorial intracerebral hemorrhage. ( 23412376 )
2013
37
Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage. ( 23662822 )
2013
38
Methylglyoxal, cognitive function and cerebral atrophy in older people. ( 22496536 )
2013
39
Cerebral atrophy in mild cognitive impairment and Alzheimer disease: rates and acceleration. ( 23303849 )
2013
40
P-selectin Expression Tracks Cerebral Atrophy in Mexican-Americans. ( 22558002 )
2012
41
Age-related cerebral atrophy in nonhuman primates predicts cognitive impairments. ( 20970891 )
2012
42
Cerebral atrophy is associated with development of chronic subdural haematoma. ( 22759238 )
2012
43
Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. ( 21596458 )
2012
44
How much do focal infarcts distort white matter lesions and global cerebral atrophy measures?. ( 23154746 )
2012
45
Transplantation of marrow stromal cells restores cerebral blood flow and reduces cerebral atrophy in rats with traumatic brain injury: in vivo MRI study. ( 21275806 )
2011
46
Intracranial air correlates with preoperative cerebral atrophy and stereotactic error during bilateral STN DBS surgery for Parkinson's disease. ( 21778795 )
2011
47
Functional abnormalities and cerebral atrophy in posttraumatic stress disorder and dementia: is there a causal link between the two diseases? ( 21314666 )
2011
48
Age-associated cerebral atrophy in mouse lemur primates. ( 19564059 )
2011
49
Rapid progressive cerebral atrophy in systemic lupus erythematosus. ( 22134797 )
2011
50
I^-Amyloid (1-42) Levels in Cerebrospinal Fluid and Cerebral Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. ( 22187546 )
2011

Variations for Cerebral Atrophy

Expression for Cerebral Atrophy

Search GEO for disease gene expression data for Cerebral Atrophy.

Pathways for Cerebral Atrophy

GO Terms for Cerebral Atrophy

Biological processes related to Cerebral Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 8.62 ADAR RNASEH2B

Sources for Cerebral Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....